Popular Articles

We Must Lead The NHS Through "dark And Dangerous Period", Says British Medical Association Consultant Chairman
The health service is entering a "dark and dangerous period" because of the economic crisis, the Chairman of the BMA"s Consultants Committee warned in a speech. Arguing that public money must not be diverted away from patient care into "the pockets of shareholders", Dr Jonathan Fielden called for private management consultants to be "ditched" from the NHS.

Healthcare Outcome Boost Needs Better Studies
Evidence suggests that outcomes in many clinical settings leave a lot to be desired, which means that research into quality improvement (QI) in clinical care has the potential to greatly improve the lot of patients. Now a study in the journal Medical Care Research and Review published by SAGE suggests that both theoretical and practical improvements in QI effectiveness studies could make these into much more powerful tools for positive change.
News of the day
ZIOPHARM Presents Positive Darinaparsin Clinical Data At ASCO's Prestigious Clinical Science Symposium
ZIOPHARM Oncology, Inc. (Nasdaq: ZIOP) announced today that it presented positive data from both Phase II intravenous (IV) and Phase I oral studies of darinaparsin (ZinaparTM or ZIO-101), the novel organic arsenic molecule, as part of the prestigious Clinical Cancer Symposia at the 45th Annual American Society of Clinical Oncology (ASCO) meeting held in Orlando, FL, May 29th to June 2nd.
Sexual Health

Clinical Lab Market In China Booming Despite Recession

Diagnostic companies looking for growth in a tough economy can still find a vibrant market for their products in China, says a leading healthcare market research publisher. IVD markets in China will grow to more than $1.5 billion in 2009, making it the world"s sixth largest IVD market. The last few years have seen market growth of 15-20%. With about 575 new hospitals opening each year and a government plan to open more than 20,000 health clinics, the lab market is booming, according to a new report, "Who is Who in Clinical Diagnostics in China (Manufacturers and Distributors Profiles, Market, Industry Overview)," from Kalorama Information, in partnership with IVD market research firm McEvoy & Farmer. Even with the current world economic problems, China"s economic growth is estimated by non-government s to be even higher than the government"s official report of about 10%. The country is urbanizing and modernizing faster than any other has in history. With greater levels of prosperity, the citizens of China will continue to seek better health care and diagnostics. According to Kalorama"s current estimates, China spends around $1.00 per person annually on diagnostics compared to $22-28 in Europe and the US -- clearly China"s IVD market has a great future. In January 2009, China"s State Council announced a major new 850 billion Yuan ($123 billion US) healthcare spending program to bring a minimum standard of medical insurance coverage to 90% of the urban and rural population. IVD companies should note that the plan also aims to upgrade hospitals and improve health centers in rural and remote areas, which will likely lead to a boom in small instrument placements at thousands of clinics and health centers across the country. China is already the world"s number two market for automated IVD instrumentation. Now a significant but completely new market for smaller, more robust instrumentation appears likely to take shape. "China is not growing as fast as they would like, and maybe is not growing to the big expectations set by recent years, but the IVD market there shows solid growth compared to other regions," says Bruce Carlson, publisher of Kalorama Information. "With new hospitals and labs opening at breakneck speed and a concerted effort by the government to modernize its healthcare system, the future looks bright." Kalorama Information"s new report, "Who is Who in Clinical Diagnostics in China (Manufacturers and Distributors Profiles, Market, Industry Overview)," produced jointly with the firm McEvoy & Farmer, is the product of on-the-ground primary research on Chinese labs conducted in fall and winter 2008. An industry overview and market size estimates are followed by profiles of 42 international diagnostic companies, 130 domestic diagnostic companies and 24 local distributors. For further information visit here. Kalorama Information


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):